Necker-Enfants Malades Hospital-ko ikertzaileekin lankidetzan egindako argitalpenak (21)

2024

  1. Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022

    eClinicalMedicine, Vol. 71

  2. Non-apoptotic FAS signaling controls mTOR activation and extrafollicular maturation in human B cells

    Science Immunology, Vol. 9, Núm. 91

2021

  1. Precision Medicine in Hematology 2021: Definitions, Tools, Perspectives, and Open Questions

    HemaSphere, Vol. 5, Núm. 3, pp. E536

  2. Total body irradiation + fludarabine compared to busulfan + fludarabine as “reduced-toxicity conditioning” for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acute Leukemia Working Party of the EBMT

    Bone Marrow Transplantation, Vol. 56, Núm. 2, pp. 481-491

2018

  1. Automated database-guided expert-supervised orientation for immunophenotypic diagnosis and classification of acute leukemia

    Leukemia, Vol. 32, Núm. 4, pp. 874-881

2017

  1. Activating mutations and translocations in the guanine exchange factor VAV1 in peripheral T-cell lymphomas

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 114, Núm. 4, pp. 764-769

  2. Is good clinical practice becoming poor clinical care?

    HemaSphere

  3. Lenalidomide maintenance compared with placebo in responding elderly patients with diffuse large B-cell lymphoma treated with first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone

    Journal of Clinical Oncology, Vol. 35, Núm. 22, pp. 2473-2481

  4. Long-term survival of patients with CLL after allogeneic transplantation: A report from the European Society for Blood and Marrow Transplantation

    Bone Marrow Transplantation, Vol. 52, Núm. 3, pp. 372-380

2016

  1. Risk factors and outcomes for patients with follicular lymphoma who had histologic transformation after response to first-line immunochemotherapy in the PRIMA trial

    Journal of Clinical Oncology, Vol. 34, Núm. 22, pp. 2575-2582

2015

  1. The EBMT/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma

    Leukemia, Vol. 29, Núm. 2, pp. 464-473

2014

  1. Rituximab maintenance obviates the poor prognosis associated with circulating lymphoma cells in patients with follicular lymphoma

    Blood

2009

  1. Flow cytometric immunobead assay for the detection of BCR-ABL fusion proteins in leukemia patients

    Leukemia, Vol. 23, Núm. 6, pp. 1106-1117

2007

  1. Characterization of a reference material for BCR-ABL (M-BCR) mRNA quantitation by real-time amplification assays: Towards new standards for gene expression measurements

    Leukemia, Vol. 21, Núm. 7, pp. 1481-1487

  2. Standards and standardization in mastocytosis: Consensus statements on diagnostics, treatment recommendations and response criteria

    European Journal of Clinical Investigation, Vol. 37, Núm. 6, pp. 435-453

2005

  1. Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: A population-matched analysis

    Leukemia, Vol. 19, Núm. 6, pp. 1029-1033

2003

  1. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 concerted action BMH4-CT98-3936

    Leukemia, Vol. 17, Núm. 12, pp. 2257-2317

  2. Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: Influence of dose and stem cell source shows better outcome with rich marrow

    Blood, Vol. 102, Núm. 8, pp. 3043-3051

2002

  1. Graft-versus-host disease and outcome in HLA-identical sibling transplantations for chronic myeloid leukemia

    Blood, Vol. 100, Núm. 12, pp. 3877-3886

1999

  1. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: Investigation of minimal residual disease in acute leukemia

    Leukemia